Market closed

Aura Biosciences/$AURA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Ticker

$AURA
Trading on

Industry

Biotechnology

Employees

89

Aura Biosciences Metrics

BasicAdvanced
$553M
Market cap
-
P/E ratio
-$1.77
EPS
0.39
Beta
-
Dividend rate
$553M
0.39
$11.39
$6.63
192K
18.543
17.768
8.503
9.942
-27.48%
-45.09%
2.89
2.89
-6.808
-10.95%
-72.31%

What the Analysts think about Aura Biosciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.

Aura Biosciences Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Aura Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AURA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aura Biosciences stock?

Aura Biosciences (AURA) has a market cap of $553M as of November 13, 2024.

What is the P/E ratio for Aura Biosciences stock?

The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of November 13, 2024.

Does Aura Biosciences stock pay dividends?

No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Aura Biosciences dividend payment date?

Aura Biosciences (AURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Aura Biosciences?

Aura Biosciences (AURA) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.